Initiating At Buy: Damora, Answering The CALR In MPNs

Research evidence excerpt

Initiating At Buy: Damora, Answering The CALR In MPNs

Biotechnology

Damora Therapeutics

TD SECURITIES (USA) LLC INITIATING COVERAGE

June 8, 2026

Price: $21.01 (06/5/2026) Initiating At Buy: Damora, Answering The

Price Target: NA CALR In MPNs

BUY (1)

ESG SCORE: 57/100

Marc Frahm, Ph.D. THE TD COWEN INSIGHT

646 562 1394

DMRA is developing best-in-class molecules for validated targets in MPN disease. Lead asset

marc.frahm@tdsecurities.com

DMR-001 is a mCALR targeted mAb for the treatment of ET and MF demonstrating 3-10x

Ellen Horste, Ph.D. potency in vitro relative to the most advanced competitor molecule, with convenient SC

646 562 1434 dosing. 001's preclinical profile addresses the high unmet need for a disease-modifying

ellen.horste@tdsecurities.com

therapy in mCALR-driven MPNs. Initiating at Buy.

Key Data

Symbol NASDAQ: DMRA DMR-001 Is A Potentially Best-In-Class mCALR-Targeted Therapy Addressing A $7B+ TAM

Beta: 1.47

Damora's lead asset DMR-001 is an Fc-null mutant-calreticulin (mCALR)-targeted antibody

52-Week Range: $34.14-$2.58

product in development for the treatment of myeloproliferative neoplasm (MPN) diseases

Market Cap: $1.3B

harboring CALR mutations (25-35% of myelofibrosis and ~25% of essential thrombocythemia).

Net Debt (MM): $(531.6)

Cash/Share: $(0.20) Proof-of-concept for mCALR-targeting as a potentially disease-modifying therapy has been

Dil. Shares Out (MM): 34.3 well established in both ET and MF by Incyte's mCALR mAb INCA033989, which demonstrated

Enterprise Value clear efficacy with clean safety in Ph I trials. '989 represents a major breakthrough in the

$187.5

(MM): treatment of MPN disease as it is the first clinical candidate to demonstrate efficacy through

BV/Share: $6.29 the specific targeting of a disease driver mutation.